Antimycobacterial extracts of a Penicillium sp. (isolate HL4-159-41B) and a Coniothyrium sp. (isolate HL6-097-027B) isolated from the rhizomes of the Canadian medicinal plant Aralia nudicaulis were found to contain palitantin (1) and botrallin (2), craterellin C (3), mycosporulone (4), spiromassaritone (5), and massarigenin D (6) respectively. Bioassays against Mycobacterium tuberculosis H37Ra revealed that 1 -4 possess moderate antimycobacterial activity.
Canadian medicinal plants have been identified as promising sources of antimycobacterial natural products [1] . Continuing our work on endophytes of Canadian medicinal plants [2] , a library of extracts derived from fungi isolated from the rhizomes of Aralia nudicaulis was screened for antimycobacterial activity. Extracts of two isolates, HL4-159-41B (Penicillium sp., Genbank accession number KF649244) and HL6-097-027B (Coniothyrium sp., Genbank accession number KP276575) showed promising activity against Mycobacterium tuberculosis H37Ra and were selected for further investigation.
An EtOAc extract of the culture broth of HL4-159-41B was found to contain palitantin (1; Figure 1 ) as the major constituent (>90% by 1 H NMR spectroscopy). The identity of 1 was confirmed by mass spectrometry, NMR spectroscopy and polarimetry, with all data being consistent with literature values [3] . Palitantin, a common metabolite of Penicillium spp. [3b, 4] , exhibited moderate activity against M. tuberculosis H37Ra and weak cytotoxicity towards HEK 293 human embryonic kidney cells (Table 1) . Although 1 has been shown to possess antiprotozoan [4a] and antifungal activities [5] , its antimycobacterial properties have not been previously reported. Bioassay guided fractionation of an EtOAc extract of the culture broth of HL6-097-027B led to the isolation of botrallin (2), craterellin C (3), a inseparable mixture of mycosporulone and 2-epimycosporulone (4), spiromassaritone (5) and massarigenin D (6) as the main constituents of the fungal extract ( Figure 1 ). The structures of 2 -6 were confirmed by mass spectrometry, NMR spectroscopy and polarimetry, with all data being consistent with literature values [6] . Mycosporulone has previously been isolated from a Coniothyrium sp. [6c], whilst spiromassaritone, massarigenin D, botrallin and craterellin C have all been isolated individually from several species of fungi [6a, b, e, f, 7] , but have neither been isolated together nor isolated from a Coniothyrium sp. fungus. Compounds 2, 3 and 4 exhibited weak to moderate activity against M. tuberculosis H37Ra although 3 and 4 showed markedly greater activity towards HEK 293 cells (Table 1) . Compunds 2 -6 have all been reported to have antimicrobial and anticancer activity [6a, b, 7-8] , but this is the first report of the antimycobacterial activity of 2, 3 and 4. in July 2012. Rhizomes were washed with water, blotted dry, cut into sections (each approximately 5 cm in length) and briefly immersed in 100% EtOH supplemented with 0.1% Tween 80 ® before being flamed until the alcohol had burned off. The sterile rhizomes were then cut transversely into 2 mm thick disks that were incubated at 25°C on 2% malt extract agar. When hyphae emerged from the cut edges of the rhizome, the fungi were subcultured to obtain pure cultures. Isolates HL4-159-41B, and HL6-097-027B were identified as previously described [9] and were found to be a Penicillium sp. (GenBank accession number KF649244) and a Coniothyrium sp. (GenBank accession number KP276575), respectively.
Biological assays: Bioassays with M. tuberculosis H37Ra (ATCC 25177) and human embryonic kidney HEK 293 cells (ATCC CRL-1573) were performed as previously described [10] .
Fermentation and extraction: HL4-159-41B was fermented with shaking (150 rpm) in 2% malt extract broth (100 mL in a 250 mL Erlenmeyer flask covered with aluminum foil) at room temperature under ambient light for 2 weeks. The fungal material was separated from the spent culture broth by vacuum filtration, and the broth was extracted with EtOAc (3 x 50 mL) to give a crude extract (49 mg). HL6-097-027B was fermented and extracted in a similar fashion (9 L of 2% malt extract broth; 90 × 100 mL batches; spent culture broth extracted with 3 × 2.7 L of EtOAc) to give a crude extract (986 mg).
Bioassay guided fractionation:
The extract of HL4-159-41B was determined to be >90% 1 by 1 H NMR and was not further fractionated. The extract of HL4-097-027B (986 mg) was dissolved in 9:1 MeOH/H 2 O (400 mL) and extracted with hexanes (3 × 200 mL) before being diluted with H 2 O (200 mL) and extracted with CH 2 Cl 2 (3 × 200 mL). The CH 2 Cl 2 fraction (379 mg) showed strong antimycobacterial activity and was subjected to size exclusion chromatography (1:1 MeOH/CH 2 Cl 2 ) over Sephadex ® LH-20 to give 2 bioactive fractions (202 mg and 77 mg). Flash column chromatography (50g SiO 2 ) of the major size exclusion column fraction using a stepwise gradient of hexanes to EtOAc (10 % increments from 100% hexanes to 100% EtOAc, 100 mL) yielded 2 fractions (23 mg and 63 mg) that were separately subjected to normal phase HPLC (7:3 hexanes/EtOAc) to give 4 (18 mg) as an inseparable mixture of epimers and 2 (2 mg), 5 (2 mg) and 6 (6 mg) respectively. The minor fraction from the size exclusion column was flash chromatographed under similar conditions to give a single bioactive fraction that, after normal phase (55:45 hexanes/EtOAc) and reverse phase HPLC (75:25 MeOH/H 2 O) gave 3 (4 mg).
